{"name":"Agitated Solutions, Inc.","slug":"agitated-solutions-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ASI-02","genericName":"ASI-02","slug":"asi-02","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Agitated Saline SoC","genericName":"Agitated Saline SoC","slug":"agitated-saline-soc","indication":"Treatment of agitation in patients with dementia","status":"phase_3"}]}],"pipeline":[{"name":"ASI-02","genericName":"ASI-02","slug":"asi-02","phase":"phase_3","mechanism":"ASI-02 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Agitated Saline SoC","genericName":"Agitated Saline SoC","slug":"agitated-saline-soc","phase":"phase_3","mechanism":"Agitated Saline SoC is a standard of care treatment that involves administering a saline solution to help calm agitated patients.","indications":["Treatment of agitation in patients with dementia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxORnk4dWRtYmxHRktjY0JKVm5CVmk2Yndaejh4aHlhLW9ackZ4X08zMmdWMk5IcHhxVWtDUVlMMFVQVlctdENQc0tJQ1ZWR0EzUWI3azlxMFlHcDB4c0NNSUZaUmZfaWgwZDE0ekF6ZWlYTGY0UnFUcDk0b19IOFo0S1NBczl5eE95Tk9xTXhxdHdjc2hMdEM0NnVjZDRQOUxBVmhJNDJwTi0tYjhiY2J0dTFWWE1kMkxMNkkxUXh1SE15b2g3eWlnRWFDNDZsMDc2TEpKMm9UTGhSdE5VamZhczU5bzBNNk8wSGpUVmJWUzBabGlLTkl5YTRSV24wY0JSR1UzVWhWemQ3VEdlRVJDTzJQTEw?oc=5","date":"2026-04-07","type":"trial","source":"The Globe and Mail","summary":"IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease - The Globe and Mail","headline":"IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNM212QXg1dkdrWFc1LXIzR0NNLWE4MDBreVN2UmR6Qk9LOEFoT3lMQTk2RUdPRUgxM3NYdlVxRENJY2Y4R3pXNmJPUUtuNTBRUE1oSUhGQnByd3lfZ0M4WmNPREx3VEhiRUxFaEZWdTdldTFOYm53Z1VhdUJpR3hDVmVqdlliUWY2cE9uLWM0WXJrM19XUlYyZzdvbUk5VlM2bUJhb3FQMDEzaUN1Vkkxd2syS3QySXVTVVg0bC1CWklVcnZHSFVoUFhzeG8xSlhGSkxpRklLbWJ0VGFVenZCOExjQXFRR2pNUWxJcGFQT2lMSHprQllQRFJrcUxSdw?oc=5","date":"2026-01-12","type":"regulatory","source":"PR Newswire","summary":"Mandara Biopharma Files IND with the FDA to Advance Dronabinol Oral Solution Formulation for Alzheimer's Agitation - PR Newswire","headline":"Mandara Biopharma Files IND with the FDA to Advance Dronabinol Oral Solution Formulation for Alzheimer's Agitation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQSUlrbkdtUGFsWTJrUGxkMEVQVXoybUNNYW9sRFZHOXZxTFZhYURScDdGMWNINUhtSV82QjBtZk9QWHdCWFN3SVdKOG5VRnBITGJQWFlZRUd2RFgzWTdaTV9sX1FGcWtBMUFKSkxsdmM4SFU4VU4xVEUtQTRlZXZPVVc0RlJCVUhCWXpXSVp2eHo0NF93SUE5MUM5TnFOUHk2cnNGRTFGdFlYZTByMU5DNG9zVS04d3h5X2VqLTJPczJkOVczQVZkLU43cVhsVGlEWWU4eEE0N2pNaENmWEJ2NE8yZ20wYlZkeHNhNDZvSHp3M0dKNTBHSnlUZnluX3RCV21OTUdn?oc=5","date":"2024-05-06","type":"trial","source":"Business Wire","summary":"Otsuka America, Inc’s. Data and Technology Company will Support Rejoyn™ Commercialization & Personalized Patient Engagement - Business Wire","headline":"Otsuka America, Inc’s. Data and Technology Company will Support Rejoyn™ Commercialization & Personalized Patient Engagem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOSEF0NWZnbGh4Tl9xcWh5SjhDR2tMRDF3REw2Vi1ad2N5dHJ1NGJVa2hnVFpGdmdFZ2FieG5FN045SndMR0FuTWRDUTRNak5DXzBWSWFZaGlXOVNLYlBhdlByMTM2ZlhOTG4yWEZRNmk0UnhZYTB4WC1KRlFrRlVpZTFUcjVPSFJhMDBiV251LVRVWFBjU1RfU2l2anB1VDRtczR1SEp1NkpuS1d6aEVoQXJsbE0zaEI4a1prYkdqNFZwZzB3LWNfOGhYRXJKUWtsUk94SWlSR29HQzA?oc=5","date":"2024-04-18","type":"deal","source":"BioSpace","summary":"Agitated Solutions Receives Health Canada License for Orbis Microbubble Generator to Streamline Cardiac Bubble Studies - BioSpace","headline":"Agitated Solutions Receives Health Canada License for Orbis Microbubble Generator to Streamline Cardiac Bubble Studies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPOXo0cGlsOHppTkFyQUV3YTV2OXpjSzFjZW1hbGlhYUYxNHpRWlV5aU1fZ1RmM081dThDMXVqWnZpdnRUVkUya1hqX1dSenM2bmNmbXRRTzFZdnMtSDhzaDlOWXpMZzc1eEplTWo2blFLNUE0VXNpOVpCWXB6ajlUUGV1VDNrUU82OTVGUVRHMHlHUk9HRGxpYUUzSWlDamNsMlNMSU1vcHZ4eDZsV3FmR2wwTWZjd3llckpNZA?oc=5","date":"2024-02-01","type":"pipeline","source":"Stock Titan","summary":"IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model - Stock Titan","headline":"IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBBdzFkWU9SX2o0UE0xZ19qR21tUm9Ob21fekZEd245UFIydzlUVTFrWUppQjN0d1o0VEt1WTRmU0R3S3R5alVzLXRHUG9qVFlBNWJmcWd0MThSQkxNdm5IemJaZm5XczEwMHBoc3JjVE8zdjlRWnc?oc=5","date":"2022-10-27","type":"pipeline","source":"Twin Cities Business","summary":"Minnesota Grants $1 Million to 43 Local Startups - Twin Cities Business","headline":"Minnesota Grants $1 Million to 43 Local Startups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQazVSYnhwQnVfdFUyUC1lZjRHOFJ4U3ZMN09Xa2k0SjJkZGpIT1VJLUZJVGZaTGpSQWVwVEtHUlFDaVRhcTM2YklrQnVpSGlvcURNbTNDazRUVnhGWGVHT2hRRTFjQ0x4dHl2MExOVHNWQ0tjbGRENlZtSW5FQk92YlhnQQ?oc=5","date":"2019-12-03","type":"pipeline","source":"Psychiatrist.com","summary":"Current and Emerging Solutions to Challenges in the Management of Alzheimer's Disease - Psychiatrist.com","headline":"Current and Emerging Solutions to Challenges in the Management of Alzheimer's Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxNZDBFYnZYVUt3Tk9mZFp4OUlBZE16SjRIN20tOE1uZkF1b2VlV2YwbzNzTVlHX3hSNmVKdk1zcHNtdUxuNmhmTXVwUlpCODBGa3FsdHRjOVR6QklQTlY5cmd0VVYtdUlKS2p0QXRpSWJmX0F5UzUzLTNabzYxRVdXaGlmLWEyZWlDMDNvdTlhazJ3bWFvQlZhM2FMbjFjNFBmSmJqZU9LenR4T0tkRVVKeWhHclFkSUpVQkQyTWlBVG9UeVdiU3JfejlZbTltSGFIcVJFZmJLelBkc2pfZW1EYnNIcFM4QWJxWGpHbUoxX2N0c3FsenBsNVNCRTFFZlBDby1Wd2F5ajEtdEhMYVNjU19zTmFSM3JhN0Z2YVVKNG0ySVlxT2FfdVBlc0Q5UGxXVVpCQg?oc=5","date":"2019-11-12","type":"pipeline","source":"PR Newswire","summary":"Avanir Pharmaceuticals, Inc. to Continue Clinical Development of Investigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia - PR Newswire","headline":"Avanir Pharmaceuticals, Inc. to Continue Clinical Development of Investigational AVP-786 for the Treatment of Agitation ","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}